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Summary A method is described enabling the direct measurement of vincristine resistance in intact tissues in
vivo by morphological study. Using the metaphase arresting properties of the drug, counts were made of
escaping anaphase and telophase mitotic figures at a range of doses. The proportion of post-metaphase mitotic
figures is called the post-metaphase index (PMI). In 95 primary intestinal tumours induced by dimethyl-
hydrazine (DMH) in rats, an increase in resistance to vincristine was shown over normal mucosa (P<0.001).
The data were analysed by computer modelling and a linear relationship is demonstrated between the logit of
the post-metaphase index, and log dose of vincristine. To achieve a PMI of 1% the fitted lines show an
enhanced vincristine dose requirement over normal mucosa of 6 times in colonic tumours, and 8 times in
small intestinal tumours. Non-neoplastic mucosa from the DMH-treated animals requires an enhanced dose
of vincristine of 1.5 times, compared with normal mucosa, to achieve a PMI of 1%.
Given current interest in the mechanism of vincristine resistance in cell lines this new approach provides a
technique for assessing the resistance of solid tumours, both in vivo and in vitro, and for subsequent
experimental manipulation.
Certain drugs, including the Vinca alkaloids and
colcemid, have the ability to arrest dividing cells
during the mitotic process, by inhibition of micro-
tubular polymerisation in the formation of the
mitotic spindle. The resulting 'arrested metaphase'
mitotic figures are readily recognisable and provide
one approach to the determination of indices of cell
proliferation by morphological means, the so-called
stathmokinetic experiment. In conventional cell-
kinetic studies a large dose of the stathmokinetic
agent is used in order to arrest all cells entering
mitosis, and at full arrest no mitotic figures appear
as anaphases or telophases. The rate of accumula-
tion of the dividing cells then gives the cell birth
rate (Tannock, 1967; Steel, 1977).
In a recent stathmokinetic study of human
colorectal carcinoma grown in organ culture
Pritchett et al. (1982) showed that tumours required
a sixfold larger dose of vincristine to achieve full
metaphase arrest than did non-neoplastic mucosa
from the same resection specimen. This in vitro
observation mirrors the disappointing clinical
experience of vincristine treatment of bowel cancer.
Much current interest relates to the biochemical,
pharmacological and genetic basis of the observed
resistance of cancer cells to chemotherapeutic
agents. In the case of resistance to the Vinca
alkaloids there is an association with the pleiotropic
multidrug resistance phenotype (Ling et al., 1983)
involving the cell surface glycoprotein P180
(Garman et al., 1983). In several studies using cell
lines of both rodent and human origin, in which
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either inherent or induced resistance was manifest,
it has been shown that a variety of calcium
transport antagonists, and other drugs will abolish
resistance (Tsuruo et al., 1982; 1983a; 1983b; Ramu
et al., 1984). This increase in sensitivity is
accompanied by increased intracellular accumu-
lation of the drug.
It is clearly of importance to understand more
about vincristine resistance and to document it
more fully in human and in vivo systems. The
normal stathmokinetic approach, as adopted by
Pritchett et al. (1982), is designed to maximise the
accuracy of estimations of cell birth rate. It is both
inappropriate and poorly adaptable to a dose-
response format, and we have therefore developed a
method of assessing the sensitivity of tissues to
vincristine not by comparing doses required for
complete arrest, but by directly assessing escape
from metaphase arrest at various doses. In the
present study we have examined the phenomenon
of vincristine resistance in dimethylhydrazine
(DMH) induced primary epithelial tumours of the
intestine in rats. This is the first documented direct
characterisation of vincristine resistance in primary
solid tumours in vivo.
Materials and methods
Rats and treatment schedules
Ninety-eight male Wistar rats (Olac Ltd, Bicester)
were used. They were maintained in standard
conditions throughout the experiment with un-
restricted access to food (Breeders diet no. 3,
Special Diet Services Ltd, Witham) and tap water.
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The animals were divided, at between 10 and 11
weeks of age, into control (30 animals) and DMH-
treated (68 animals) groups. The DMH-treated
animals received a long-term, low-dose schedule of
DMH (Aldrich Chemical Co. Ltd, Dorset)
exposure, comprising 24 subcutaneous injections,
administered at one week intervals, of a dose of
20mg (of base) kg-1 body weight. Animals were
killed at least two weeks after the final dose of
DMH to allow recovery from any acute toxic
effects.
Vincristine experiment
The animals of both treated and untreated groups
were allocated at random into six vincristine dosage
groups (Oncovin, Eli Lily Ltd, Basingstoke) ranging
from 1.0mg kg- 1 body weight, a full metaphase
arresting dose for rat colonic epithelial cells in vivo,
to 0.01 mgkg-1 body weight. Vincristine was
administered during a period in which the rats were
between 38 and 45 weeks old, an age at which
previous experience had shown that tumours are
frequent, while morbidity due to tumour effects is
still low. The control animals were divided equally
into six groups of 5 animals. The DMH-treated
animals were divided into two groups of 12 animals
(for doses 1.Omgkg-' and 0.Olmgkg- 1) and four
groups of 11 animals. Vincristine was administered
as a single i.p. injection given between 0900h and
1100h to minimise effects of diurnal variation. All
animals were killed 2h after vincristine administra-
tion by cervical dislocation, and autopsy was
performed immediately. The small bowel was
dissected free and fixed unopened for at least 10h
in Carnoy's fluid. The colon was dissected free with
a margin of anal skin, opened along its length, and
pinned to a cork board prior to Carnoy fixation.
The tissues were subsequently transferred to
cellosolve. Following fixation the specimens were
carefully examined for tumours. Transverse blocks
of the bowel were taken through each tumour, and
through non-neoplastic bowel at two sites prone to
tumour development, viz. 20mm distal to the
pylorus, and at the junction of the middle and
lower thirds of the colon. Corresponding blocks
were obtained from the control group. All these
blocks were processed routinely to paraffin wax;
histological sections prepared at 4,m were stained
with haematoxylin and eosin prior to counting.
Counting procedures and statistical analysis
The histological sections were counted as follows:
Whole circumferential sections of non-neoplastic
mucosa from either control or DMH-treated
animals were counted for the low doses of
vincristine, and half or one third circumferences for
higher dose groups where metaphase arrest was
more complete and mitotic figures thus much more
numerous. Total numbers of mitotic figures in
metaphase, arrested metaphase, anaphase and
telophase were obtained, together with the total of
unequivocal post-metaphase figures. The morpho-
logy of prophase is difficult to define, and it was
decided to exclude this phase of mitosis from the
study, although the possibility remains that some
late prophase figures may have been included as
metaphases. Using the counting methods described,
the number of all mitoses counted in each section
was 100-200 for low-dose groups and 200-300 for
high dose groups. In the case of tumours, areas of
viable neoplastic tissue were selected at hazard and
similar counts made. The total mitoses counted for
each tumour was 100-300. In the subsequent
analysis the total mitoses are designated 'm' and
total post-metaphase figures 'a'.
The ratio of post-metaphase figures (anaphases
and telophases) to all mitoses is the Post-Metaphase
Index (PMI = a/m). The relationship between the
PMI, which is an index of the degree of escape
from metaphase arrest, and the dose of vincristine
was analysed using the computer program GLIM
(Baker & Nelder, 1978). The PMI was transformed
to the logit
logit PMI = loge PMI1- PMI]
lo, a
m-a
We selected the logit transformation, rather than a
log1o transformation because of the nature of the
observations. Thus for each observed mitotic figure
there are two 'all or nothing' options viz.
metaphase or post-metaphase. This yields data in
the form of a biological assay with quantal
responses for which one possible transformation is
the logistic (Finney, 1978). We found that this
transformation together with transformation of
vincristine dose to log1o dose, was the most satis-
factory in order to linearise our data. These trans-
formed data were plotted and the slopes of the
fitted lines calculated by the computer model. The
data for small bowel and large bowel were analysed
separately: at both sites there are three tissues
represented, comprising normal mucosa, DMH-
treated but not neoplastic mucosa, and tumour.
These were designated Control, DMH, and Tumour
respectively. In both small and large bowel analysis
of deviance was performed to test for the
significance of differences between the slopes of the
fitted lines for each of the three types of tissue.
Finally, the fitted lines were used to estimate the
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doses of vincristine required to achieve a PMI of
1% (-logit PMI 0.01=4.60) for each tissue, and
the result expressed as a ratio of control. A PMI of
1% is achieved in the middle of the range of the
doses used.
Results
In the untreated animals there were no tumours.
The number of tumours in the DMH-treated
animals is shown in Table I. A total of 95 tumours
was identified in 39 animals, 29 of the DMH-
treated group being tumour free. The same range of
tumour morphology was observed as that seen
previously in DMH-treated rats (Sunter et al.,
1978), but all the variants were analysed together.
Table I Distribution of intestinal tumours in the DMH-
treated animals by anatomical site and vincristine dosage
group
Anatomical
site No. of tumours
Vincristine dose (mg kg 1 body weight)
1.00 0.50 0.25 0.10 0.05 0.01
Colon 11 9 1 9 8 11
Small intestine 18 2 5 7 5 9
Total 29 11 6 16 13 20 (95)
The mean PMI for each combination of site and
tissue at each dose of vincristine, together with the
standard error, is shown in Table II. For each of
the tissues there is a progressive rise in metaphase
escape (an increasing PMI) as the dose of vin-
cristine administered decreases. This relationship is
not linear, there being a rapid increase in PMI over
the lowest two doses. Over the whole range of
doses tumour tissue from both anatomical sites
shows more metaphase escape than either of the
other two tissues. At high, and intermediate doses,
the DMH-treated tissue also shows increased escape
over control tissue, although the effect is not as
marked. The PMI in each tissue in the absence of
vincristine, i.e. the 'native' PMI, was not
determined, except for a few DMH-treated animals
killed prior to vincristine administration for
humane reasons. The mean PMI of mucosa from
these animals (corresponding to DMH in Table II)
was 15% in the colon and 19% in the small
intestine. These latter data have not been incor-
porated in the analysis; they were derived from
animals killed before the full course of DMH-
treatment, and no similar data are available for
tumour or control tissue. Despite the imprecision
and possible inaccuracy inherent in these estimates,
it appears that the lowest vincristine dose may be
associated with some measurable metaphase arrest
in this tissue.
Because the relationship between PMI and dose
Table II Effect of vincristine dose on the PMI (%) in each site/tissue
combination. Standard errors are included in parenthesis, and were calculated by
the method of Snedecor and Cochran (1971)
PMI %
Colon Small intestine
Vincristine
dose (mgkg-') Control DMH Tumour Control DMH Tumour
0.01 19.36 10.25 11.86 7.85 7.90 14.72
(0.92) (0.93) (0.91) (1.05) (0.92) (0.80)
0.05 2.24 3.43 7.38 0.62 1.49 6.81
(0.48) (0.41) (0.90) (0.15) (0.20) (1.03)
0.10 0.23 0.76 4.13 0.17 0.19 2.19
(0.10) (0.18) (0.63) (0.09) (0.07) (0.55)
0.25 0.07 0.36 0.30 0.00 0.03 1.13
(0.06) (0.10) (0.15) (0.02) (0.26)
0.50 0.00 0.09 0.25 0.00 0.00 0.00
(0.04) (0.12)
1.00 0.00 0.07 0.19a 0.00 0.06 0.24a
(0.05) (0.06) (0.04) (0.11)
'A single animal in this group bearing 2 colonic and 4 small intestinal tumours
showed a mean tumour PMI of 6.2%. Either vincristine administration was faulty,
or these tumours were exceptionally resistant. We have excluded the animal from
the analysis and from this table.
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is non-linear two options for statistical analysis
were considered viz. simple significance testing
between mean PMI's at individual dosage points, or
transformation of the data to achieve linearity with
subsequent significance testing for differences
between the slopes of the fitted lines. We have
chosen the second option because it enables us to
look for differences between tissues in their
response to vincristine over the whole range of
doses, using all the data for each test of
significance.
Application of the GLIM program, using the
transformation logit PMI and loglo dose, shows the
relationship between the transformed values of PMI
and vincristine dose to be linear. The fitted lines for
each site/tissue combination are shown in Figure 1.
Because the analysis gives more weight to data
points for which larger numbers of post-metaphase
figures were seen, i.e. in low dose groups, the fitted
lines lie somewhat below the data points. We have
plotted the negative logit PMI because the PMI is a
measure of escape from metaphase arrest, and we
prefer to consider the phenomenon in terms of
increasing arrest plotted against increasing
vincristine dose. At any given dose of vincristine
tumour tissue shows the least degree of metaphase
arrest, and control mucosa the most. DMH-treated,
non-neoplastic mucosa shows an intermediate
degree of vincristine sensitivity. For control and
DMH-treated mucosae metaphase arrest appears to
be rather more complete in the small intestine than
in the colon for the same dose of vincristine. There
is little difference in this respect between small-
intestinal and colonic tumours. Analysis of deviance
was used to test for differences between the slopes
of the fitted lines at each anatomical site and the
results are shown in Table III. Significant differ-
Table III Comparison of slopes of fitted dose response
lines. The differences between slopes are shown, together
with the standard errors of the differences
Control- Control- DMH-
Site DMH Tumour Tumour
Colon 1.44+ 0.36a 2.13 + 0.34a 0.69 + 0.20a
Small intestine 0.85 +0.46b 1.97 +0.43a 1.12 + 0.22a
ap<0.001; bNot significant.
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ences in sensitivity to vincristine are shown in the
colon between all tissues, and in the small bowel
between all but control and DMH-treated mucosae.
The equations of the fitted lines were used to
estimate the relative vincristine doses required, as a
proportion of control tissue requirement, to achieve
a PMI of 0.01. For tumour tissue the increased
dose required is 6 times that of control mucosa in
the colon, and 8 times in the small intestine. The
corresponding values for DMH-treated mucosa are
1.6 times in the colon and 1.4 times in the small
intestine.
Discussion
The PMI and tumour resistance to vincristine
We have shown, using a method measuring directly
the escape of dividing cells from metaphase arrest,
that induced primary tumours of the large and
small bowel are more resistant to the stathmo-
kinetic effect of vincristine than normal mucosa.
Carcinogen-treated, but non-neoplastic mucosa
shows an intermediate degree of vincristine resist-
ance. These results are in keeping with other data
derived from human colorectal tumour tissue and
normal mucosa, but using a different method of
assessing vincristine resistance (Pritchett et al.,
1982). That study showed an in vitro requirement
for complete stathmokinesis of 3.0 Mg ml - 1 for
tumours and 0.5ugml-1 for mucosa. Comparable
data from the study of inherent vincristine resist-
ance in murine colonic tumour cell lines shows an
enhanced cytotoxic dose requirement of up to
approximately tenfold in sensitive cell lines
(Tsuruo et al., 1983a).
From in vitro studies in cell lines biochemical and
pharmacological data have convincingly demon-
strated a cellular biochemical mechanism under-
lying vincristine resistance. The resistance of
primary solid tumours to chemotherapy has been
attributed, at least in part, to other factors. Poor
tumour vascularity (Selby et al., 1979) and changes
in vascularity following 'therapy may be relevant,
together with the cell-cycle phase dependency of
some chemotherapeutic agents (Valeriote & Van
Putten, 1975). Consideration of methodology, in
both the present study and in our former study
(Pritchett et al., 1982) provides some insight into
the possible contributions of these various factors
towards the phenomenon that we have described.
Some effect due to poor tumour vascularity is not
excluded in the present study and we have not
ascertained tissue concentrations of vincristine.
Thus the data relates to administered doses which
may not reflect tissue levels. Clearly this will not
affect differences between DMH-treated and
normal mucosae, and in the in vitro system it is
irrelevant. Given the dependence of the experi-
mental system on the perturbation of mitosis
induced by vincristine, the cell-cycle phase-
specificity of this mechanism is axiomatic. The
reported observations relate to the effects of a first,
and brief, exposure to vincristine. There can be no
question, therefore, of induced alterations of
tumour vascularity or cell-cycle synchronisation.
We conclude that the phenomenon we have
demonstrated reflects one aspect of vincristine
resistance at an underlying cellular level.
The relationship between the cytotoxic and the
stathmokinetic actions of vincristine is not resolved.
The doses required to achieve complete metaphase
arrest in various human and rodent epithelia are in
considerable excess of those used as maximum
doses in human cancer therapy. Despite this, such
therapeutic doses are efficacious as cytotoxic agents
to some solid tumours. Furthermore it has been
shown that sensitivity to the Vinca alkaloids is
manifest in G1 and in S, as well as in the mitotic
phase of the cell cycle (Mauro & Madoc-Jones,
1970). Vincristine is also associated with other non-
cycle related metabolic disturbances within the cell
which may be of importance in cytotoxicity.
The pragmatic issue in terms of the potential
usefulness of the PMI in the investigation of drug
resistance is not whether stathmokinesis and
cytotoxicity are equivalent, but rather whether
resistance results from the same mechanism in both.
Pharmacological manipulation of vincristine resis-
tance using cell lines shows that a number of drugs
including many calcium transport antagonists will
overcome it, and cause increased intra-cellular
accumulation of vincristine. We are presently
investigating the effect of verapamil on the PMI of
colonic tumour tissue using both human and
animal models.
The validity of this approach to vincristine
resistance using the PMI depends upon several
factors: Does vincristine alter the flux of cells
through the cell cycle? Is there any evidence that
vincristine causes disproportionate prolongation of
any of the morphological phases of mitosis other
than the production of metaphase arrest? Are there
any differences in the 'native' PMI of different
tissues of sufficient magnitude to affect inter-
pretation of the results? The extensive literature
concerning the use of vincristine as a stathmo-
kinetic agent has been comprehensively reviewed
(Wright & Appleton, 1980). Although the specific
problems generated by the present study have not
been discussed previously, there is indirect evidence
to help answer the above questions.
High doses of vincristine inhibit the flux of
lymphoid cells through G2 by inhibition of DNA
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synthesis (Fitzgerald & Brehaut, 1970), and are also
associated with increased degeneration of arrested
metaphase figures (Smith et al., 1974; Clarke, 1971).
However, the doses used in the present experiment
are in the range of the 'standard' doses described
by Jellinghaus et al. (1977), and Clarke (1971), and
do not affect the flux of cells into S-phase in the
rodent intestine.
There is no evidence in the literature to suggest
any effect of vincristine on mitotic phase duration,
other than the primary effect on microtubule
formation and inhibition of anaphase.
Pozharisski et al. (1982) while studying kinetic
aspects of carcinogenesis in non-neoplastic mucosa
using the DMH model noted that the proportion of
anaphases and telophases prior to DMH treatment
changed only slightly following treatment (from
17% to 20%). In the present study we were able to
demonstrate a 'native' PMI in DMH-treated
colonic mucosa of 15% and in DMH-treated small
intestine 19%. Despite the imprecision of these
latter observations, it is possible that there may or
may not be minor differences between the PMI's of
individual tissues. Use of the GLIM analysis to
compare the rates of change of PMI with increasing
vincristine dose, rather than significance testing for
differences between PMI's at individual vincristine
dosage points eliminates this problem in the
comparison of different tissues. Pozharisski further
states that up to 60% of mitotic figures in DMH-
treated tissues are abnormal. Certainly it would be
anticipated that more chromosomal bridges would
occur in tumour tissue. These would tend to reduce
the proportion of metaphases generating normal
post-metaphase figures. We have found a greater
proportion of post-metaphase figures at each dose
in tumour tissue despite this diluting effect of
mitotic abnormality.
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